Basal-like breast cancers (BLBCs) are known for rapid progression, high rates of metastasis and relapse, and poor long-term survival. BLBC cells are notoriously resistant to agents commonly used to treat breast cancer (chemotherapeutics, estrogen antagonists).
Learn more about Enhanced Targeting of Basal-like Breast Cancer Through 'Cooperation Response Genes'
Basal-like breast cancer (BLBC) is an aggressive, hard-to-treat cancer, with frequent metastasis, recurrence, and poor long-term survival. BLBCs are resistant to cancer-selective agents used to treat breast cancers (e.g., Tamoxifen and Herceptin). Thus, standard of care for BLBC involves highly cytotoxic chemotherapeutic agents that still fail in ˜80% of cases.
Learn more about Cancer Selective Targeting Through a Cancer Specific Gene Network